Sarcoma fusion-derived neoantigen

Sarcoma-specific gene fusion breakpoint peptides are unique amino acid sequences generated at the junction of two genes that have undergone chromosomal translocation, a hallmark of many mesenchymal tumors (Source 1.2.2). These chimeric sequences are entirely tumor-specific and are not expressed in normal tissues, making them ideal neoantigens for targeted immunotherapy (Source 1.3.2). Common examples include the EWSR1-FLI1 fusion in Ewing sarcoma, the SS18-SSX fusion in synovial sarcoma, and the PAX3-FOXO1 fusion in alveolar rhabdomyosarcoma (Source 1.2.1, 1.4.5). When these fusion proteins are processed by the proteasome, the resulting breakpoint-spanning peptides can be presented on the cell surface by Major Histocompatibility Complex (MHC) molecules (Source 1.4.1). Therapeutic strategies, such as peptide or mRNA vaccines and engineered T-cell receptor (TCR) therapies, aim to stimulate the immune system to recognize these neoepitopes and selectively eliminate the malignant cells (Source 1.1.1, 1.5.2). Despite their high specificity, challenges remain regarding the low immunogenicity of some junctional sequences and the potential for tumor immune escape through HLA downregulation (Source 1.4.2, 1.5.2). Clinical trials have explored various vaccine formats, including liposomal and dendritic cell-based deliveries, to enhance the immune response against these targets (Source 1.3.1, 1.4.1). The identification of these peptides relies on advanced genomic sequencing and HLA-binding prediction algorithms to select the most promising candidates for personalized therapy (Source 1.1.3, 1.4.4).

Other names

Sarcoma-specific gene fusion breakpoint peptidesFusion-derived neoepitopesBreakpoint-spanning peptidesChimeric fusion peptidesSarcoma fusion-derived neoantigens

Induction of a cytotoxic T-lymphocyte (CTL) response by presenting tumor-specific junctional peptides on Major Histocompatibility Complex (MHC) molecules, leading to the selective destruction of fusion-positive sarcoma cells.